-14%

est. 2Y upside i

HealthcareSeries D+

Rank

#2698

Sector

Health Tech / SaaS

Est. Liquidity

~2Y

Data Quality

Data: Medium

Rare European healthcare marketplace with genuine monopoly moat and concrete IPO catalyst in 12-24 months. $6.4B at 16x revenue is reasonable. $866M preferences (13.5%) moderate.

Last updated: March 22, 2026

Bull (25%)+90%

IPO 2026 at 30-35x rev (~$12-14B); European expansion accelerates.

Base (55%)+30%

IPO 2026-2027 at $8-9B (20x on $440M).

Bear (20%)-35%

IPO delayed; growth slows sub-10%; valuation compresses to $4B.

Est. time to liquidity~1.5 years

Preference Stack Risk

moderate

Funding Intensity

14%

$866M on $6.4B (13.5%).

Dilution Risk

low

Pre-IPO; no expected major rounds.

Secondary Liquidity

limited

Pre-IPO tender possible.

View all 261 open roles at Doctolib →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Doctolib's data — designed to show you've done your homework.

  • 1

    “Monetizing practitioner data/pharma CRM?”

  • 2

    “Target IPO multiple?”

  • 3

    “Tender/secondary for employees?”

Community

Valuation Sentiment

Our model estimates -14% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.